Gold prices steady ahead of Fed decision, Trump’s tariff deadline
Michelle LaSpaluto, the Chief Financial Officer of Chimerix Inc . (NASDAQ:CMRX), has recently sold 2,260 shares of the company's common stock, according to a regulatory filing. The transaction comes as the stock trades near its 52-week high of $4.65, having delivered an impressive return of over 400% in the past six months. The shares were sold at an average price of $4.5113, amounting to a total transaction value of $10,195. This sale was executed on February 13, 2025, as part of an automatic sell-to-cover arrangement to address tax liabilities incurred from a restricted stock unit award. Following this transaction, LaSpaluto retains ownership of 172,977 shares in the company. According to InvestingPro analysis, Chimerix maintains a strong balance sheet with more cash than debt, and its current ratio of 6.33 indicates robust short-term liquidity. Subscribers can access 17 additional ProTips and a comprehensive Pro Research Report for deeper insights into CMRX's financial health.
In other recent news, TD Cowen, via analyst Joseph Thome, has highlighted ten key biotech catalysts expected to generate significant investor interest by 2025. These include anticipated clinical trial data releases and regulatory milestones from firms such as ANAB, UTHR, QURE, ALKS, JAZZ, PRME, XENE, PTCT, RAPP, and CMRX. Meanwhile, H.C. Wainwright has reaffirmed its Buy rating for Chimerix (CMRX), following the company's recent submission of a New Drug Application for accelerated approval of dordaviprone (ONC201) to the FDA. The firm is optimistic about a potential launch for dordaviprone in the third quarter of 2025. In other developments, Chimerix has announced the amendment and extension of its Officer Severance Benefit Plan, which now extends its term for an additional three years from November 12, 2024. These updates reflect recent developments in the biotech sector and provide investors with key information to monitor in the coming years.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.